Developer docs
API playgroundTry for free, no card

Search company profiles

MY01

Full company profile

uuid00008p1

Namestring
MY01
Legal namestring
MY01 Inc.
Websiteurl
my01.io
Company typeenum
Private
Founded yearint
2015
Descriptiontext

MY01 is a Montreal-based medical device company founded in 2015 as a spin-off from McGill University (via parent company Nxtsens Microsystems) that develops FDA-cleared continuous intracompartmental pressure monitors for the diagnosis of acute compartment syndrome. Its core technology is the Continuous Perfusion Sensing Technology (CPST) platform, which uses Micro-Electro-Mechanical Systems (MEMS) sensors to provide real-time, continuous digital pressure readings of limb compartments — a capability demonstrated in published clinical evidence to be 600% more accurate than competing devices (Synthes, STIC) and to enable diagnosis approximately 4 hours earlier than traditional methods. The product ecosystem comprises the MY01 Continuous Compartmental Pressure Monitor hardware, a Bluetooth-enabled mobile application with FDA-cleared perfusion pressure calculation, a hospital-grade base station, and a SOC 2 Type II compliant cloud-based monitoring platform.

The company serves hospital trauma centers, orthopedic surgeons, emergency physicians, and U.S. military medical units across the United States, Canada, the United Kingdom, and the European Union. MY01 operates a primarily enterprise field sales go-to-market supplemented by channel partnerships (national US distributor network, LEDA Orthopedics in the UK, Optimal Healthcare Advisors for trauma center outcomes), with direct sales leadership including a US Director of Sales and a Chief Commercial Officer. Revenue is generated through hardware device sales bundled with cloud platform access, with reimbursement economics anchored by Medicare NTAP (up to $2,112.50 per inpatient case), TPT for outpatient settings through 2028, and CPT code 20950.

MY01 has shipped 2,000+ devices and documented 1,000+ clinical cases as of late 2024, with a team of 50 employees from 20 countries. Total disclosed funding is approximately $16 million across a $12.5M Series A led by Investissement Québec (April 2023), a $2.5M BioMed Propulsion grant (September 2024), $1.15M CAD from Canada Economic Development (August 2024), and a strategic investment by Joe Kiani, founder of Masimo, who joined the board in September 2025.

Short descriptiontext

MY01 is a medical device company that develops FDA-cleared MEMS-based continuous intracompartmental pressure monitors for acute compartment syndrome diagnosis. Its CPST platform serves hospital trauma centers, orthopedic surgeons, and military medical units across North America, UK, and EU markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
compartment pressure monitoring, intracompartmental pressure monitor, trauma care sensors, MEMS medical devices, continuous perfusion sensing
Industry4 codes
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHDAHALAB
Pressure & Force Sensors (Pressure/Strain/Load Cells)
SECONDARYHDAHAAAG
Sensors, MEMS & Imaging ICs
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Compartment Pressure Monitoring Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Continuous Compartment Pressure Monitor Device Sales
TypeHardware Sales
Description

Sale of the FDA-cleared MY01 Continuous Compartmental Pressure Monitor device to hospitals and trauma centers. The device is a hardware product with no consumables required, making it suitable for trauma settings.

my01.io
2Cloud-Based Monitoring Platform
TypeSubscription Recurring
Description

Cloud-based pressure monitoring platform accessible to healthcare providers for patient care, research, and education. Part of the overall service offering bundled with device.

my01.io
3Medicare NTAP and TPT Reimbursement
TypeTransaction Fee
Description

Medicare reimbursement through NTAP (New Technology Add-on Payment) for inpatient and TPT (Transitional Pass-Through) for outpatient settings. NTAP provides up to $2,112.50 additional payment per case.

my01.io
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Medicare NTAP Reimbursement - Inpatient
ModelTransaction based/ take rateBilling cadencePer procedure
Notes

NTAP provides maximum new technology add-on payment of $2,112.50 for FY2026. ICD-10-PCS code XX2F3W9 for inpatient hospital cases.

my01.io
2Medicare TPT Reimbursement - Outpatient
ModelTransaction based/ take rateBilling cadencePer procedure
Notes

HCPCS code C1742 for outpatient/ASC settings. APC + Charges × Cost-to-Charge Ratio payment model. Valid October 1, 2025 through September 30, 2028.

my01.io
3CPT Code 20950 - Monitoring of interstitial fluid pressure
ModelUnit PricingBilling cadencePer procedure
Notes

2025 Medicare Physician Fee Schedule: $87.02. 2025 Hospital OPPS APC Payment: $703.59.

my01.io
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Continuous Perfusion Sensing Technology (CPST)
Description

MY01's proprietary platform providing real-time, objective continuous perfusion pressure data for bedside patient monitoring

my01.io
Core offering1 text field

MY01 develops, manufactures, and sells the FDA-cleared MY01 Continuous Compartmental Pressure Monitor—an all-in-one, consumable-free hardware device that uses MEMS-based sensors to deliver continuous, real-time intracompartmental pressure readings, paired with a Bluetooth-connected mobile application and cloud-based Continuous Perfusion Sensing Technology (CPST) platform for hospitals, trauma centers, and orthopedic surgeons diagnosing acute compartment syndrome.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 4 hours earlier diagnosis compared to traditional methods
+5 more records
Product overview1 text field

MY01 offers a unified medical device ecosystem centered on the Continuous Compartmental Pressure Monitor and its companion Mobile Application, both FDA-cleared. The system is built on the Continuous Perfusion Sensing Technology (CPST) Platform, which integrates real-time intracompartmental pressure monitoring with perfusion pressure calculations. The MY01 Base Station provides infrastructure support for hospital settings. Together, these products enable continuous monitoring that can detect compartment syndrome 4 hours earlier than traditional methods.

Product and service4 records
1MY01 Continuous Compartmental Pressure Monitor
CategoryContinuous Compartment Pressure Monitor
Description

FDA-cleared, all-in-one, consumable-free hardware device that uses MEMS sensor technology to provide continuous intracompartmental pressure monitoring, enabling earlier diagnosis of acute compartment syndrome in trauma patients at hospital trauma centers.

2MY01 Mobile Application
CategoryCompanion Mobile Software Application
Description

Bluetooth-enabled iOS and Android mobile application that connects to the MY01 monitor and displays real-time pressure data, trend information, and perfusion pressure calculations with patient-specific diastolic blood pressure inputs for healthcare providers.

3MY01 Base Station
CategoryClinical Accessory Hardware
Description

Charging station and connectivity hub for the MY01 Continuous Compartmental Pressure Monitor, available with a mobile device cart and companion tablet option for hospital and clinical use.

4Continuous Perfusion Sensing Technology (CPST) Platform
CategoryCloud-based Patient Monitoring Platform
Description

Integrated bedside patient monitoring platform that combines the MY01 hardware monitor and mobile application into a unified solution, delivering real-time, objective continuous perfusion pressure data with cloud connectivity, trend analytics, and clinical decision support for healthcare providers.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1U.S. Army (Defense Logistics Agency)
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-03-16
Description

Official contributor to 2026 Best Medic Competition at Joint Base San Antonio-Camp Bullis. Received National Stock Number (NSN) for flagship Pressure Monitor enabling military medical unit procurement.

prnewswire.com
2Optimal Healthcare Advisors
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-24
Description

Partnership to help trauma centers transform real-time data into measurable outcomes. OHA provides expertise in care quality improvement, documentation streamlining, and outcomes measurement for trauma centers implementing MY01 technology.

my01.io
3U.S. Distributor Network
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-12-20
Description

New distribution partnerships expanding MY01's national presence across the United States, strengthening mission to improve patient outcomes and enable trauma centers with actionable insights.

my01.io
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

Selected for C100 Growth Program providing access to Canadian tech executives, venture capital networks, and Silicon Valley expertise for accelerated growth.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-05-29
Description

UK distribution partnership making MY01's continuous compartment pressure monitoring technology available to surgeons and patients throughout the United Kingdom. LEDA Orthopedics serves as the exclusive distribution partner for UK market expansion.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Parent company and engineering partner. Nxtsens developed and manufactures the MEMS sensor technology. MY01 spun off from Nxtsens which originated as McGill University Master's project. Nxtsens won 2nd place at McGill Dobson Cup in 2016.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the largest orthopedic medical device companies in the world. Stryker acquired C2Dx and offers STIC compartment pressure monitoring products that compete directly with MY01 in trauma centers, and brings an enormous orthopedic sales force and bundled contracting leverage.

TypeDirect peer
Description

German medical device specialist focused on pressure measurement and tubing systems, including compartment pressure monitoring solutions used in orthopedic trauma. Directly comparable product offering and clinical application to MY01's continuous pressure monitor.

TypeBroad incumbent
Description

Global leader in noninvasive patient monitoring technologies (pulse oximetry, rainbow sensors). Joe Kiani, Masimo's founder, is on MY01's board. Comparable as a connected clinical-grade vital signs monitoring company and natural strategic acquirer or platform partner.

TypeBroad incumbent
Description

Medical device company focused on IV therapy, infusion pumps, and connected patient monitoring. Comparable business model combining hardware devices with software/connectivity, and operates in similar hospital procurement channels.

TypeBroad incumbent
Description

Global medical device and pharmaceutical company with a strong portfolio in infusion systems, patient monitoring, and surgical solutions. Comparable hospital-customer base and complementary pressure/fluid monitoring portfolio.

TypeBroad incumbent
Description

One of the world's largest medical device companies with extensive patient monitoring, orthopedic, and connected care offerings. Comparable as a broad incumbent in hospital-based continuous monitoring and orthopedic trauma markets.

7Royal Philips
TypeBroad incumbent
Description

Global health technology company with a major patient monitoring and connected care division serving hospitals worldwide. Comparable as a connected bedside monitoring platform incumbent that could compete with or acquire MY01's CPST platform.

TypeBroad incumbent
Description

Major medical equipment and patient monitoring company offering continuous vital signs monitoring systems to hospitals globally. Comparable as a broad incumbent in clinical-grade bedside monitoring with overlapping hospital customer base.

TypeBroad incumbent
Description

Global medical device company with a significant orthopedic trauma and sports medicine franchise. Comparable orthopedic trauma customer base and hospital sales channels that overlap with MY01's target buyer profile.

TypeBroad incumbent
Description

Leading orthopedic medical device company with deep trauma center relationships and a broad orthopedic surgical portfolio. Comparable hospital customer base in orthopedic trauma where MY01's compartment pressure monitor is used.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MY01

Compartment Pressure Monitoring Devicesmy01.io

MY01 is a medical device company that develops FDA-cleared MEMS-based continuous intracompartmental pressure monitors for acute compartment syndrome diagnosis. Its CPST platform serves hospital trauma centers, orthopedic surgeons, and military medical units across North America, UK, and EU markets.

What MY01 does

MY01 is a Montreal-based medical device company founded in 2015 as a spin-off from McGill University (via parent company Nxtsens Microsystems) that develops FDA-cleared continuous intracompartmental pressure monitors for the diagnosis of acute compartment syndrome. Its core technology is the Continuous Perfusion Sensing Technology (CPST) platform, which uses Micro-Electro-Mechanical Systems (MEMS) sensors to provide real-time, continuous digital pressure readings of limb compartments — a capability demonstrated in published clinical evidence to be 600% more accurate than competing devices (Synthes, STIC) and to enable diagnosis approximately 4 hours earlier than traditional methods. The product ecosystem comprises the MY01 Continuous Compartmental Pressure Monitor hardware, a Bluetooth-enabled mobile application with FDA-cleared perfusion pressure calculation, a hospital-grade base station, and a SOC 2 Type II compliant cloud-based monitoring platform.

The company serves hospital trauma centers, orthopedic surgeons, emergency physicians, and U.S. military medical units across the United States, Canada, the United Kingdom, and the European Union. MY01 operates a primarily enterprise field sales go-to-market supplemented by channel partnerships (national US distributor network, LEDA Orthopedics in the UK, Optimal Healthcare Advisors for trauma center outcomes), with direct sales leadership including a US Director of Sales and a Chief Commercial Officer. Revenue is generated through hardware device sales bundled with cloud platform access, with reimbursement economics anchored by Medicare NTAP (up to $2,112.50 per inpatient case), TPT for outpatient settings through 2028, and CPT code 20950.

MY01 has shipped 2,000+ devices and documented 1,000+ clinical cases as of late 2024, with a team of 50 employees from 20 countries. Total disclosed funding is approximately $16 million across a $12.5M Series A led by Investissement Québec (April 2023), a $2.5M BioMed Propulsion grant (September 2024), $1.15M CAD from Canada Economic Development (August 2024), and a strategic investment by Joe Kiani, founder of Masimo, who joined the board in September 2025.

MY01 firmographics

Firmographics
Name
MY01
Legal name
MY01 Inc.
Website
https://my01.io
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
MY01 is a medical device company that develops FDA-cleared MEMS-based continuous intracompartmental pressure monitors for acute compartment syndrome diagnosis. Its CPST platform serves hospital trauma centers, orthopedic surgeons, and military medical units across North America, UK, and EU markets.
Ownership category
akta.pro rank

MY01 industry classification

Industry
Product category
Compartment Pressure Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHDAHALAB
Pressure & Force Sensors (Pressure/Strain/Load Cells)
SECONDARYHDAHAAAG
Sensors, MEMS & Imaging ICs

Keywords

  • Compartment pressure monitoring
  • Intracompartmental pressure monitor
  • Trauma care sensors
  • MEMS medical devices
  • Continuous perfusion sensing

Where MY01 is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

MY01 business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Continuous Compartment Pressure Monitor Device Sales: Sale of the FDA-cleared MY01 Continuous Compartmental Pressure Monitor device to hospitals and trauma centers. The device is a hardware product with no consumables required, making it suitable for trauma settings.
  2. Cloud-Based Monitoring Platform: Cloud-based pressure monitoring platform accessible to healthcare providers for patient care, research, and education. Part of the overall service offering bundled with device.
  3. Medicare NTAP and TPT Reimbursement: Medicare reimbursement through NTAP (New Technology Add-on Payment) for inpatient and TPT (Transitional Pass-Through) for outpatient settings. NTAP provides up to $2,112.50 additional payment per case.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePer procedureMedicare NTAP Reimbursement - Inpatient
Transaction based/ take ratePer procedureMedicare TPT Reimbursement - Outpatient
Unit PricingPer procedureCPT Code 20950 - Monitoring of interstitial fluid pressure

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

MY01 product offering

Product offering

Core offering

MY01 develops, manufactures, and sells the FDA-cleared MY01 Continuous Compartmental Pressure Monitor—an all-in-one, consumable-free hardware device that uses MEMS-based sensors to deliver continuous, real-time intracompartmental pressure readings, paired with a Bluetooth-connected mobile application and cloud-based Continuous Perfusion Sensing Technology (CPST) platform for hospitals, trauma centers, and orthopedic surgeons diagnosing acute compartment syndrome.

Product overview

MY01 offers a unified medical device ecosystem centered on the Continuous Compartmental Pressure Monitor and its companion Mobile Application, both FDA-cleared. The system is built on the Continuous Perfusion Sensing Technology (CPST) Platform, which integrates real-time intracompartmental pressure monitoring with perfusion pressure calculations. The MY01 Base Station provides infrastructure support for hospital settings. Together, these products enable continuous monitoring that can detect compartment syndrome 4 hours earlier than traditional methods.

Differentiator

Problem solved

Functional benefit

Brands

  • Continuous Perfusion Sensing Technology (CPST): MY01's proprietary platform providing real-time, objective continuous perfusion pressure data for bedside patient monitoring

Products and services

  • MY01 Continuous Compartmental Pressure Monitor FDA-cleared, all-in-one, consumable-free hardware device that uses MEMS sensor technology to provide continuous intracompartmental pressure monitoring, enabling earlier diagnosis of acute compartment syndrome in trauma patients at hospital trauma centers.
  • MY01 Mobile Application Bluetooth-enabled iOS and Android mobile application that connects to the MY01 monitor and displays real-time pressure data, trend information, and perfusion pressure calculations with patient-specific diastolic blood pressure inputs for healthcare providers.
  • MY01 Base Station Charging station and connectivity hub for the MY01 Continuous Compartmental Pressure Monitor, available with a mobile device cart and companion tablet option for hospital and clinical use.
  • Continuous Perfusion Sensing Technology (CPST) Platform Integrated bedside patient monitoring platform that combines the MY01 hardware monitor and mobile application into a unified solution, delivering real-time, objective continuous perfusion pressure data with cloud connectivity, trend analytics, and clinical decision support for healthcare providers.

Quantifiable outcome

  • 4 hours earlier diagnosis compared to traditional methods
  • +5 more outcomes

Companies that use MY01

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

MY01 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

MY01 partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • U.S. Army (Defense Logistics Agency)coreGTM or Marketing Partner · 16 March 2026Official contributor to 2026 Best Medic Competition at Joint Base San Antonio-Camp Bullis. Received National Stock Number (NSN) for flagship Pressure Monitor enabling military medical unit procurement.
  • Optimal Healthcare AdvisorscoreStrategic or Co-development Partner · 24 September 2025Partnership to help trauma centers transform real-time data into measurable outcomes. OHA provides expertise in care quality improvement, documentation streamlining, and outcomes measurement for trauma centers implementing MY01 technology.
  • U.S. Distributor NetworkcoreChannel Partner/ Reseller/ Distributor · 20 December 2024New distribution partnerships expanding MY01's national presence across the United States, strengthening mission to improve patient outcomes and enable trauma centers with actionable insights.
  • C100minorStrategic or Co-development Partner · 1 September 2024Selected for C100 Growth Program providing access to Canadian tech executives, venture capital networks, and Silicon Valley expertise for accelerated growth.
  • LEDA OrthopedicscoreChannel Partner/ Reseller/ Distributor · 29 May 2024UK distribution partnership making MY01's continuous compartment pressure monitoring technology available to surgeons and patients throughout the United Kingdom. LEDA Orthopedics serves as the exclusive distribution partner for UK market expansion.
  • Nxtsens MicrosystemscoreStrategic or Co-development PartnerParent company and engineering partner. Nxtsens developed and manufactures the MEMS sensor technology. MY01 spun off from Nxtsens which originated as McGill University Master's project. Nxtsens won 2nd place at McGill Dobson Cup in 2016.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

MY01 competitors and assessment

Company assessment

Direct peers

  • Stryker: One of the largest orthopedic medical device companies in the world. Stryker acquired C2Dx and offers STIC compartment pressure monitoring products that compete directly with MY01 in trauma centers, and brings an enormous orthopedic sales force and bundled contracting leverage.
  • Raumedic AG: German medical device specialist focused on pressure measurement and tubing systems, including compartment pressure monitoring solutions used in orthopedic trauma. Directly comparable product offering and clinical application to MY01's continuous pressure monitor.

Broad incumbents

  • Masimo: Global leader in noninvasive patient monitoring technologies (pulse oximetry, rainbow sensors). Joe Kiani, Masimo's founder, is on MY01's board. Comparable as a connected clinical-grade vital signs monitoring company and natural strategic acquirer or platform partner.
  • ICU Medical: Medical device company focused on IV therapy, infusion pumps, and connected patient monitoring. Comparable business model combining hardware devices with software/connectivity, and operates in similar hospital procurement channels.
  • Baxter International: Global medical device and pharmaceutical company with a strong portfolio in infusion systems, patient monitoring, and surgical solutions. Comparable hospital-customer base and complementary pressure/fluid monitoring portfolio.
  • Medtronic: One of the world's largest medical device companies with extensive patient monitoring, orthopedic, and connected care offerings. Comparable as a broad incumbent in hospital-based continuous monitoring and orthopedic trauma markets.
  • Royal Philips: Global health technology company with a major patient monitoring and connected care division serving hospitals worldwide. Comparable as a connected bedside monitoring platform incumbent that could compete with or acquire MY01's CPST platform.
  • GE HealthCare: Major medical equipment and patient monitoring company offering continuous vital signs monitoring systems to hospitals globally. Comparable as a broad incumbent in clinical-grade bedside monitoring with overlapping hospital customer base.
  • Smith+Nephew: Global medical device company with a significant orthopedic trauma and sports medicine franchise. Comparable orthopedic trauma customer base and hospital sales channels that overlap with MY01's target buyer profile.
  • Zimmer Biomet: Leading orthopedic medical device company with deep trauma center relationships and a broad orthopedic surgical portfolio. Comparable hospital customer base in orthopedic trauma where MY01's compartment pressure monitor is used.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

MY01 social profiles

Digital presence

MY01 compliance and trust

Trust signal

Compliance2 records

MY01 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MY01 leadership team

Management profile

Number of profiles

Profiles9 records

MY01 funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MY01 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MY01

What does MY01 do?

MY01 develops, manufactures, and sells the FDA-cleared MY01 Continuous Compartmental Pressure Monitor—an all-in-one, consumable-free hardware device that uses MEMS-based sensors to deliver continuous, real-time intracompartmental pressure readings, paired with a Bluetooth-connected mobile application and cloud-based Continuous Perfusion Sensing Technology (CPST) platform for hospitals, trauma centers, and orthopedic surgeons diagnosing acute compartment syndrome.

Is MY01 a public or private company?

MY01 is a private company. It is classified as venture growth investor backed and is currently operating.

When was MY01 founded?

MY01 was founded in 2015. It employs 11 to 50 people.

Where is MY01 based?

MY01 is headquartered in Montreal, Canada, in the North America region.

How does MY01 make money?

Three revenue lines are on record. Continuous Compartment Pressure Monitor Device Sales are the primary driver. The others are cloud-Based Monitoring Platform and medicare NTAP and TPT Reimbursement.

Who are MY01's main competitors?

Direct peers on record are Stryker and Raumedic AG. Broad incumbents are Masimo, ICU Medical, Baxter International, Medtronic, Royal Philips, GE HealthCare, Smith+Nephew and Zimmer Biomet.

Does MY01 have an API?

No public API is recorded for MY01.

What industry is MY01 in?

MY01's product category is Compartment Pressure Monitoring Devices. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comAugmented Reality in Surgery: Mixed Reality Navigation Platform Growth Driven by Spine, Orthopedic, and Neurosurgical ApplicationsQYResearch released a market analysis report estimating the global Mixed Reality Navigation Platform market at US$ 205 million in 2025, projected to reach US$ 402 million by 2032 with a 10.3% CAGR, as the FDA's Digital Health Center of Excellence listed 104 AR medical devices by December 2025, a 167% increase from 39 entries in 2022. Augmedics announced FDA 510(k) clearance for its X2 next-generation AR headset in November 2025 with 100% increased field of view, while recent clinical studies including the RIDERS trial demonstrated that AR-guided surgery significantly improves outcomes with 52% lesion positivity versus 13% for standard care in robotic prostatectomy. The competitive landscape includes Brainlab SE, Medivis Inc., Novarad Corporation, Medacta International SA, Zimmer Biomet Holdings, MY01, and CLARO Surgical as key players advancing AI-integrated surgical AR solutions.openPR.comAnalysis of Segments and Major Growth Areas in the Pediatric Perfusion MarketThe pediatric perfusion market is projected to grow to $4.39 billion by 2030, representing a compound annual growth rate (CAGR) of 9.2%, driven by advances in critical care technologies, increased investments in pediatric healthcare infrastructure, and wider adoption of ECMO in pediatric respiratory failure. In March 2023, LivaNova, a UK-based medical device manufacturer, received FDA 510(k) clearance and launched the Essenz Heart-Lung Machine in the US, an integrated perfusion system for cardiopulmonary bypass surgeries designed for both adult and pediatric use. In September 2025, US-based OrthoPediatrics Corp. formed a distribution partnership with MY01 Inc. to expand global access to MY01's Continuous Perfusion Sensing Technology Platform for pediatric trauma care.PR NewswireMY01 Bolsters U.S. Army Medical Readiness as Official Contributor to 2026 Best Medic Competition and Announces New Military National Stock Number (NSN)MY01, a medical technology company specializing in limb perfusion injury diagnosis, announced two milestones in its U.S. military partnership: formal support of the 2026 CSM Jack L. Clark Jr. Best Medic Competition held at Joint Base San Antonio-Camp Bullis in January 2026, and receipt of a National Stock Number (NSN) from the Defense Logistics Agency for its flagship Continuous Compartmental Pressure Monitor and associated training device. The NSN enables military medical units worldwide to order MY01 devices through the standard federal supply system, representing a critical step toward broader military procurement adoption.YahooMY01 Welcomes Joe Kiani as Investor and Board Member to Accelerate Innovation in Connected Patient MonitoringJoe Kiani, founder of Masimo, invested in MY01 and joined its board. The company's CPST platform detects limb perfusion injuries, with a study showing 4-hour earlier diagnosis. MY01 plans to expand CPST and pioneer cardiogenic shock monitoring.YahooMY01 Welcomes Joe Kiani as Investor and Board Member to Accelerate Innovation in Connected Patient MonitoringMY01, a Montreal-based medical technology company specializing in continuous perfusion sensing technology for limb perfusion injuries, announced that Joe Kiani has invested in the company and joined its Board of Directors. Kiani, founder of Masimo and the Patient Safety Movement Foundation, brings significant credibility in medical innovation to support MY01's expansion of its CPST Platform. A recent study of 100 patients demonstrated clinicians using CPST diagnosed 4 hours earlier than traditional methods with 100% efficacy.PR NewswireMY01 Welcomes Joe Kiani as Investor and Board Member to Accelerate Innovation in Connected Patient MonitoringMY01, a medical technology company, has welcomed Joe Kiani as an investor and board member to support advancements in its continuous perfusion sensing technology (CPST). Kiani's investment is expected to enhance MY01's efforts to reduce variability in healthcare and improve outcomes for patients with limb injuries. MY01 aims to expand its CPST Platform while also pursuing innovations in cardiogenic shock monitoring.GlobeNewswireOrthoPediatrics Corp. Announces Distribution Agreement with MY01 Inc.OrthoPediatrics Corp. announced a distribution partnership with MY01 Inc. to expand access to MY01's Continuous Perfusion Sensing Technology for pediatric patients at risk of acute compartment syndrome. The collaboration combines MY01's platform with OrthoPediatrics' pediatric sales force and medical education to reduce care variability.PR NewswireMY01 Continuous Pressure Monitor surpasses 1000 case milestoneMY01, Inc. announced it has served its 1000th patient with its Continuous Pressure Monitor device designed for diagnosing compartment syndrome, a limb-threatening condition often resulting from trauma. The device uses Microelectromechanical Systems (MEMS) technology to provide objective, real-time intracompartmental pressure measurements as an alternative to subjective clinical assessments. CEO Charles Allan stated the milestone reflects the company's growing adoption as a diagnostic standard in clinical settings.Pulse 2.0MY01 Raises $12.5 Million To Develop Microsensors For Aiding PhysiciansMY01, a medical technology company specializing in microsensors for diagnosing compartment syndrome, has secured $12.5 million in Series A funding led by Investissement Quebec with participation from Desjardins Capital and Fondaction. The capital will be utilized to expand commercialization activities within the United States market. This investment aims to accelerate product development and establish MY01's Continuous Compartmental Pressure Monitor as the standard for diagnosis.BetaKitMY01 raises $12.5 million CAD for microsensors that aid in physician diagnosticsMontréal-based medtech startup MY01 secured $12.5 million CAD in Series A funding led by Investissement Québec to expand commercialization activities in the United States. The company utilizes microsensors for its Continuous Compartmental Pressure Monitor, a device approved by the FDA as a breakthrough technology for diagnosing acute compartment syndrome.